# Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy

> **NCT00228969** · PHASE2 · COMPLETED · sponsor: **SK Life Science, Inc.**

## Conditions studied

- Refractory Epilepsy

## Interventions

- **DRUG:** RWJ-333369

## Key facts

- **NCT ID:** NCT00228969
- **Lead sponsor:** SK Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** — (—)
- **Last updated:** 2012-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00228969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00228969, "Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00228969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*